SABCS 2020 | CONTESSA: tesataxel in HR+ breast cancer
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the CONTESSA study (NCT03326674), a multicenter, randomized Phase III study of tesetaxel in patients with HER2-negative, HR-positive, locally advanced or metastatic breast cancer, previously treated with a taxane in the neoadjuvant setting. Tesetaxel was compared with capecitabine in this patient population and the combination approach demonstrated improved outcomes for the enrolled patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.
